Outlook Therapeutics, Inc. (OTLK) Form 8-K — Jul 23, 2026
Outlook Therapeutics granted stock options to purchase 100,000 shares to CEO Robert C. Jahr and 210,078 shares to CFO Lawrence A. Kenyon at an exercise price of $1.4304 per share. The options vest on July 21, 2027, subject to continued service, and were granted under the 2024 Equity Incentive Plan.
Key figures
- Bonus ceo
- 420000
- Bonus cfo
- 200000
- Vesting date
- 2027-07-21
- Exercise price
- 1.4304
- Options granted ceo
- 100000
- Options granted cfo
- 210078
- Fda approval deadline
- 2026-07-31
Price after filing
1 day: +6.4%7 days: -21.2%30 days: -51.0%
Close on the filing date to close N calendar days later (from $1.32). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.